Mindray No. 1, China’s Top 100 Most Influential Pharmaceutical Enterprises Released in 2021
China‘s dongshiju.com and http://datatechnology.com.cn/ jointly released the Seventh China’s Top 100 Most Influential Pharmaceutical Enterprises in 2021 。The list is mainly assessed from the marketing management indicators, financial indicators and innovation indicators, and then weighted and summarized by the experts of the jury. Finally, the top 100 pharmaceutical enterprises such as Mindray medical, Sinopharm, Wantai Biopharma and Yunnan Baiyao are determined.
The top 100 Chinese pharmaceutical companies in 2021 are based on pharmaceutical companies listed on the Shanghai and Shenzhen main boards, the SME board, the ChiNext, the Beijing Stock Exchange and the New Third Board.
Among them, the marketing management indicators mainly assess the brand awareness, market appeal, market share of main products, etc. The financial indicators are mainly based on the assessment of the latest financial report data of the enterprise, such as total assets, operating revenue, net profit, revenue growth rate, profit growth rate, etc. Innovation indicators assess the investment of enterprises in technological product R & D and business model innovation, as well as their response to the guidance of national macro policies and industrial development trends. In this ranking, Mindray medical, the leader of domestic medical devices, ranks first.
Through statistical analysis, it is found that more than half of the medical device enterprises are listed in the top 100. In addition to Mindray medical, dozens of enterprises including BGI, Shengxiang BioTech, Lepu Medical, Wego Orthopedics, Andon Medical, Intco Medical and Yuwell medical have entered the list, involving in vitro diagnosis, orthopedics, cardiovascular, gene testing, rehabilitation, ophthalmology and other fields.
According to public data, the main revenue of Chinese medical device manufacturers in 2019 was about 720 billion yuan. From 2021 to 2022, the main revenue of medical device manufacturers is expected to exceed trillion yuan, and the compound growth rate of China’s medical device industry will continue to maintain at about 15%. Compared with the growth rate of about 5% of the global medical device market in the past five years, China’s medical device market will maintain a high-speed expansion trend in the future, and its proportion in the global market scale will be further increased.
It should be noted that in the above half of the medical device enterprises, most enterprises are committed to research and development of products in the field of external diagnostics, thanks to the outbreak of COVID-19 in recent two years.
According to the financial reports of the past two years, affected by the epidemic, the performance of in vitro diagnosis enterprises such as Shengxiang biology, DaanGene and Intco Medical have ushered in collective high growth. As a whole, six of the top ten net profit growth in the medical device sector are in vitro diagnosis enterprises. During the epidemic, in vitro diagnosis industry has seen a series of listed companies and a large number of financing events. Data show that China has become one of the fastest growing markets for in vitro diagnostics in the world.
According to statistics,，In 2019, the scale of China’s IVD market exceeded 90 billion yuan. From January to May 2021, the export volume of China’s main diagnostic reagent products reached 42.846 billion yuan.
Article from:：Qixiezhijia
BradyKnows has seasoned staff in registration and can help manufacturers on legal compliance. If you have any questions, please feel free to contact us info@bradyknowsmedical.com for more information.
